Understanding the natural history of hypereosinophilia and hypereosinophilic syndromes
Study of Clinical Profiles of Patients Followed for Chronic Hypereosinophilia and/or Hypereosinophilic Syndrome by the Creation of a National Cohort
This study looks at how unexplained high eosinophil levels and related syndromes affect patients over time to better understand their symptoms and the factors that might influence their condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Sex | All |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille) |
| Trial ID | NCT04018118 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the natural history of unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES). It will analyze the clinical and biological characteristics of patients, focusing on their evolutionary profiles and potential genetic and environmental factors. The study will categorize patients based on their disease progression, ranging from single flare-ups to chronic conditions requiring ongoing treatment. By collecting biological samples, the research seeks to uncover the underlying mechanisms of these syndromes and their impact on organ health.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with hypereosinophilia or hypereosinophilic syndrome, particularly those with eosinophil counts above 1500/mm3.
Not a fit: Patients with known HIV infection or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of hypereosinophilia and its associated syndromes, improving patient outcomes.
How similar studies have performed: While there is limited data on the natural history of HE and HES, similar studies on eosinophilic disorders have shown promise in understanding disease mechanisms.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men or Women of any age : * With the diagnosis criteria of hyperosinophlia OR hypereosinophilic syndrome OR specific organ eosinophilic disease according to the consensus conference of the International Cooperative Working Group on Eosinophil Disorders (ICOG-EO) * With an AEC \> 1500/mm3 or organ damage related to the presence of eosinophils in the tissues or organs whatever the context (idiopathic, clonal or reactive, including drug-related, parasitic or allergic) * HES diagnosis since 2005/01/01 * Patients socially insured * Patient who agreed to participate to the study, its proceedings and duration. Exclusion Criteria: * Known HIV infection * Not socially insured * Person unable to receive a enlighten information * Person who refuse to sign the consent * Persons deprived of their liberty * Persons benefiting from a system of legal protection (tutelage / guardianship)
Where this trial is running
Lille
- Hôpital Roger Salengro, CHU — Lille, France (Recruiting)
Study contacts
- Principal investigator: Guillaume Lefevre — University Hospital, Lille
- Study coordinator: Guillaume Lefevre, MD
- Email: Guillaume.lefevre@chru-lille.fr
- Phone: 03 20 44 55 72
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.